EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Hydrocortisone for prevention or treatment of bronchopulmonary dysplasia: long-term neurodevelopmental safety and efficacy—a meta-analysis of randomized clinical trials

Kawthar Ahmed Shehab, Rahaf Muslih N Almatrafi, Ethar Ali, Yara Albargi, Sama Saabi, Halah Alhassan Aljohani, Rayan Nabil Almuhanna, Raghad Alnaami, Khalid Abdulrahman Almehery, Reema Safar Alamri, Sarah Ahmed A Baqer, Shouq Naif Aloufi und 2 weitere

Frontiers in Pediatrics · 24.06.2026 · 14

DOI: 10.3389/fped.2026.1851870 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 24.06.2026. Verfasst von Kawthar Ahmed Shehab und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Postnatal systemic steroids can reduce inflammation that contributes to bronchopulmonary dysplasia (BPD) in extremely preterm infants; however, prior experience with dexamethasone raised concerns regarding long-term neurodevelopmental harm. As a result, hydrocortisone has been proposed as a potentially safer alternative.

Methods

We conducted a meta-analysis of randomized controlled trials comparing hydrocortisone with placebo/routine care in preterm infants, stratified by early prophylaxis (<7 days) or late treatment (≥7 days). We searched major databases through February 2026. The primary outcome was the composite of death or neurodevelopmental impairment (NDI) at 2 years of corrected age.

Results

We included 17 studies representing seven distinct trials and their follow-up publications, comprising a total of 2,213 infants (1,096 receiving hydrocortisone and 1,117 receiving placebo). At 2 years, death/NDI occurred in 53.5% (531/993) of infants in the hydrocortisone group and 56.8% (581/1,023) of infants in the placebo group, with no significant effect observed with either early administration [risk ratio (RR) 0.89, 95% CI 0.70–1.13; I ²=0%] or late administration (RR 0.97, 95% CI 0.80–1.17; I ²=0%). Hydrocortisone was not associated with significant differences in death at 2 years (17.1% vs. 20.8%) or NDI at 2 years (42.5% vs. 43.9%) nor in cerebral palsy, hearing impairment, or visual impairment. Exploratory analyses showed no significant reduction in death or BPD at 36 week of postmenstrual age overall, and available school-age outcomes did not demonstrate differences in neurocognitive measures.

Conclusion

Across randomized trials with long-term follow-up, postnatal hydrocortisone was not associated with improved survival free of NDI at 2 years nor was it associated with an increased risk of major neurodevelopmental or sensory impairments. These findings do not demonstrate an increased neurodevelopmental risk with hydrocortisone as used in current regimens, but its use should still be individualized based on respiratory phenotype, timing, and short-term monitoring for steroid-related adverse effects. Systematic Review Registration PROSPERO CRD420261280132

Schlagwörter

Stichwörter der Autor:innen

bronchopulmonary dysplasiahydrocortisonemeta-analysispreterm infantssafety

Autor:innen und Institutionen

  • College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • College of Medicine, Northern Border University, Arar, Saudi Arabia.
  • College of Medicine, Ahfad University for Women, Omdurman, Sudan.
  • College of Medicine, Jazan University, Jazan, Saudi Arabia.
  • College of Medicine, Istanbul University, Istanbul, Türkiye.
  • College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia.

Zitieren

APA

Shehab, K. A., Almatrafi, R. M. N., Ali, E., Albargi, Y., Saabi, S., Aljohani, H. A., Almuhanna, R. N., Alnaami, R., Almehery, K. A., Alamri, R. S., Baqer, S. A. A., Aloufi, S. N., Elaraby, A., & Alnawfal, B. M. (2026). Hydrocortisone for prevention or treatment of bronchopulmonary dysplasia: long-term neurodevelopmental safety and efficacy—a meta-analysis of randomized clinical trials. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1851870

Vancouver

Shehab KA, Almatrafi RMN, Ali E, Albargi Y, Saabi S, Aljohani HA, et al. Hydrocortisone for prevention or treatment of bronchopulmonary dysplasia: long-term neurodevelopmental safety and efficacy—a meta-analysis of randomized clinical trials. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1851870

BibTeX
@article{Shehab2026,
  author = {Shehab, Kawthar Ahmed and Almatrafi, Rahaf Muslih N and Ali, Ethar and Albargi, Yara and Saabi, Sama and Aljohani, Halah Alhassan and Almuhanna, Rayan Nabil and Alnaami, Raghad and Almehery, Khalid Abdulrahman and Alamri, Reema Safar and Baqer, Sarah Ahmed A and Aloufi, Shouq Naif and Elaraby, Ahmed and Alnawfal, Bedah Mohammed},
  title = {Hydrocortisone for prevention or treatment of bronchopulmonary dysplasia: long-term neurodevelopmental safety and efficacy—a meta-analysis of randomized clinical trials},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1851870}
}
Kostenlos starten →